APPRAISAL SPECIFIC PROJECTS

These are projects commissioned by NICE in relation to the appraisal of specific technologies under the Multiple Technology Appraisal (MTA) and Single Technology Appraisal (STA) programmes.

To receive notification when new reports or documents are uploaded on to this website, please join our mailing list by entering your details on the right of this page or follow us on Twitter @NICE_DSU

Alzheimer's disease - donepezil, rivastigmine, galantamine and memantine

Age-related macular degeneration - ranibizumab and pegaptanib

Ankylosing spondylitis - adalimumab, etanercept and infliximab

Breast cancer - lapatinib

Crohn's disease - adalimumab and infliximab

Colorectal cancer - cetuximab

Diabetes - dapagliflozin

Diabetes - liraglutide

Lung cancer - erlotinib

Lupus - belimumab

Macular oedema - bevacizumab

Myelodysplastic syndromes - azacitidine

Osteoporosis - alendronate, etidronate, risedronate, raloxifene, teriparatide and strontium ranelate

Prostate cancer - degarelix

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus

Rheumatoid arthritis - adalimumab, etanercept and infliximab

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use)

Rheumatoid arthritis - adalimumab, etanercept, inflizimab, certolizumab pegol, golimumab, abatacept and tocilizumab 

Rheumatoid arthritis - tocilizumab

 

To receive notification when new reports or documents are uploaded to this website, please join our mailing list by entering your details on the right of this page or follow us on Twitter @NICE_DSU